These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33219385)

  • 41. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
    Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters.
    Yamazaki S
    J Clin Pharmacol; 2018 Aug; 58(8):1053-1060. PubMed ID: 29723430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.
    Pfeifer ND; Bridges AS; Ferslew BC; Hardwick RN; Brouwer KL
    J Pharmacol Exp Ther; 2013 Dec; 347(3):737-45. PubMed ID: 24080682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
    Varma MV; Lai Y; Feng B; Litchfield J; Goosen TC; Bergman A
    Pharm Res; 2012 Oct; 29(10):2860-73. PubMed ID: 22638872
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
    Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
    Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions.
    Stopfer P; Giessmann T; Hohl K; Hutzel S; Schmidt S; Gansser D; Ishiguro N; Taub ME; Sharma A; Ebner T; Müller F
    Br J Clin Pharmacol; 2018 Sep; 84(9):1941-1949. PubMed ID: 29665130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
    Wang Q; Zheng M; Leil T
    CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):228-238. PubMed ID: 28296193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of total hepatic clearance by combining metabolism, transport, and permeability data in the in vitro-in vivo extrapolation methods: emphasis on an apparent fraction unbound in liver for drugs.
    Poulin P
    J Pharm Sci; 2013 Jul; 102(7):2085-95. PubMed ID: 23613473
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
    Xu R; Ge W; Jiang Q
    Eur J Clin Pharmacol; 2018 Jun; 74(6):755-765. PubMed ID: 29453492
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Scutellarin is Highly Likely to be Responsible for Drug-Drug Interactions Mediated by Hepatic Organic Anion-Transporting Polypeptide1B3.
    Liu J; Guo Y; Xu Y; Yuan L; Zhu H
    Pharm Res; 2020 Oct; 37(12):232. PubMed ID: 33123800
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    Eur J Pharm Sci; 2021 Oct; 165():105932. PubMed ID: 34260894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach.
    Iwasaki S; Kosugi Y; Zhu AZX; Nakagawa S; Sano N; Funami M; Kosaka M; Furuta A; Hirabayashi H; Amano N
    Xenobiotica; 2019 Nov; 49(11):1251-1259. PubMed ID: 30516093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation.
    Venkatakrishnan K; Obach RS
    Curr Drug Metab; 2007 Jun; 8(5):449-62. PubMed ID: 17584016
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
    Johnson M; Patel D; Matheny C; Ho M; Chen L; Ellens H
    Drug Metab Dispos; 2017 Jan; 45(1):27-34. PubMed ID: 27737931
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Strategy for the Prediction of Steady-State Exposure of Digoxin to Determine Drug-Drug Interaction Potential of Digoxin With Other Drugs in Digitalization Therapy.
    Srinivas NR
    Am J Ther; 2019; 26(1):e54-e65. PubMed ID: 26808357
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized" animal models.
    Jaiswal S; Sharma A; Shukla M; Vaghasiya K; Rangaraj N; Lal J
    Drug Metab Rev; 2014 Nov; 46(4):475-93. PubMed ID: 25270219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.
    Xue C; Zhang X; Cai W
    Pharmaceutics; 2017 Dec; 10(1):. PubMed ID: 29267251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.